HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
XERS
Xeris Biopharma Holdings, Inc.
XERS lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
XERS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Strong | |
| Strong |
XERS's revenue, cash flow and balance sheet are currently healthy, and its profitability is stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
XERS PE Valuation
XERS has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
XERS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
XERS has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
XERS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.34 | — |
| Q3 2026 | -$0.04 | +$0.05 |
| Q2 2026 | -$0.10 | +$0.10 |
| Q1 2026 | $0.07 | +$0.36 |
| Q4 2025 | $0.00 | +$0.37 |
| Q3 2025 | -$0.09 | +$0.36 |
| Q2 2025 | -$0.20 | +$0.23 |
| Q1 2025 | -$0.29 | +$0.18 |
| Q4 2024 | -$0.37 | +$0.08 |
XERS has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over XERS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
XERS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $107.2M | +44% |
| Q2 2026 | $92.1M | +29% |
| Q1 2026 | $83.1M | +38% |
| Q4 2025 | $85.8M | +43% |
| Q3 2025 | $74.4M | +37% |
| Q2 2025 | $71.5M | +49% |
| Q1 2025 | $60.1M | +48% |
| Q4 2024 | $60.1M | +35% |
XERS's revenue has grown year over year every quarter since late 2020: $107M last quarter, up 44% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 16% | +6.7 points |
| Q2 2026 | 5.6% | -0.6 points |
| Q1 2026 | 9.5% | +15 points |
| Q4 2025 | 20% | +17 points |
| Q3 2025 | 9.1% | +33 points |
| Q2 2025 | 6.3% | +23 points |
| Q1 2025 | -5.1% | +30 points |
| Q4 2024 | 2.8% | +25 points |
XERS has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
XERS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $35.5M | +92% |
| Q2 2026 | $8.3M | +4440% |
| Q1 2026 | $9.9M | +$19.9M |
| Q4 2025 | $20M | +915% |
| Q3 2025 | $18.4M | +$26.7M |
| Q2 2025 | $182K | +$10.5M |
| Q1 2025 | -$10M | +$10.3M |
| Q4 2024 | $2M | -74% |
XERS has burned cash in most quarters: $74M over the past year, about seven times what it generated the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over XERS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
XERS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.9% | +17.1M shares |
| 1 year | +6.9% | +12.3M shares |
| 3 years | +38% | +51.9M shares |
| 5 years | +186% | +124M shares |
| Available history | +603% | +163M shares |
XERS has 190M diluted shares, up 6.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | $365,000 |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | $63,000 |
| Q4 2019 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
XERS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 3.5x | Elevated |
| Q1 2026 | 2.9x | Moderate |
| Q4 2025 | 4.2x | High |
| Q3 2025 | 11.5x | High |
XERS's net debt is about 1.2 years of its operating earnings (EBITDA), down from 12 years a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
XERS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 85.9 | Overbought |
| Stochastic | 93.8 | Overbought |
XERS's weekly RSI is 86 (overbought) and its Stochastic is 94 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
XERS PE vs Healthcare Sector
| Metric | XERS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
XERS has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
XERS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.5 | 45% above |
| 20 week MA | $9.57 | 74% above |
| 50 week MA | $7.79 | 114% above |
| 100 week MA | $6.68 | 149% above |
| 200 week MA | $4.49 | 271% above |
XERS has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
XERS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.45 | $5.45 | -27% |
| 2021 | $5.45 | $2.59 | -52% |
| 2022 | $2.59 | $1.26 | -51% |
| 2023 | $1.26 | $2.35 | +87% |
| 2024 | $2.35 | $3.43 | +46% |
| 2025 | $3.43 | $7.37 | +115% |
| 2026 YTD | $7.37 | $16.7 | +126% |
XERS has the edge over HIMS on returns for 2026, with the stronger performance.